Month: November 2024

Ajman Municipality & Planning Department Recognized with Multiple Honors at HBC 2024 International Awards

Ajman, UAE – The Ajman Municipality & Planning Department achieved outstanding recognition at the HBC 2024 International Awards held on November 9 in Riyadh. The ceremony celebrated international excellence and drew distinguished guests, including H.E. Almarri Lieutenant General Mohammed Ahmed, Director General of the General Directorate of Residency and Foreigners Affairs – Dubai; His Excellency Dr. Engineer Saad bin Ahmed Al Muhannadi, President of Qatar’s Public Works Authority; His Excellency Dr.Wahdan Al Qadi, CEO of the Saudi Investment Fund for Events; and Dr. Emmanuel Cerroni, Director General of HBC.

Achievements of Ajman Municipality & Planning Department at HBC 2024:

  • Innovative Idea Gold Award: Virtual Asset Counting System – Ajman Municipality & Planning Department was recognized for its groundbreaking Virtual Asset Counting System, a cutting-edge solution designed to optimize the management of municipal assets. By integrating advanced AI and 3D technologies, the system has revolutionized asset tracking, reducing the time required for asset counting from one month to just seven days and cutting costs by 80%. This initiative has provided a comprehensive QR-based database of over 32,000 assets, setting a benchmark for operational efficiency and technological innovation in municipal management.

Event Highlights: The HBC 2024 Awards recognized 60 winners across 28 categories, representing over 5,000 assessment hours and 3,741 applications. With the global launch of the Intelligent Sustainable Excellence (ISE) Model and the introduction of the HBC Quality of Life Award, the event underscored a commitment to advancing standards that enhance societal well-being.

Congratulations to Ajman Municipality & Planning Department for its accomplishments. These awards underscore their dedication to innovation, excellence, and sustainable urban development.

For more information, please visit https://hbcworld.org/cases

Media Contact
Company Name: Harvard Business Council
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://hbcworld.org/cases

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ajman Municipality & Planning Department Recognized with Multiple Honors at HBC 2024 International Awards

AD Ports Group Recognised with Multiple Honors at HBC 2024 International Awards

Abu Dhabi, UAE – AD Ports Group achieved outstanding recognition at the HBC 2024 International Awards held on November 9 in Riyadh. The ceremony celebrated international excellence and drew distinguished guests, including H.E. Lieutenant General Mohammed Ahmed Al Marri, Director General of the General Directorate of Residency and Foreigners Affairs in Dubai; His Excellency Dr. Engineer Saad bin Ahmed Al Muhannadi, President of Qatar’s Public Works Authority; and Dr. Emmanuel Cerroni, Director General of HBC.

Achievements of AD Ports Group at HBC 2024:

  • Professional Gold Award:
    • Mr. Mohamed Al Qubaisi, Operations Manager – Mr. Al Qubaisi was recognized for his significant impact in optimising port operations, driving cost efficiencies, and enhancing health and safety practices at Zayed Port. His dedication to improving customer satisfaction and operational standards exemplifies excellence within AD Ports Group.
  • Professional Diamond Award:
    • Dr.Souraj Salah, Director of Process Improvement – Dr. Salah’s work in Lean Six Sigma applications has transformed processes across the organization, achieving substantial cost savings and a 96% reduction in lead times. His commitment to continual improvement has positioned AD Ports Group as a leader in process optimisation and operational excellence.
  • Women Leader Gold Award:
    • Ms. Tasha Sawchuk, VP of Strategy Development – Ms. Sawchuk received accolades for her strategic vision and dedication to advancing women’s roles within maritime and logistics. Her leadership has significantly contributed to AD Ports Group’s strategic development and long-term growth.
  • Health & Safety Gold Award:
    • OFCO Offshore, AD Ports Group – OFCO was awarded for its comprehensive health and safety practices, which adhere to OHSAS 18001 and OSHAD SF standards. Their commitment to rigorous safety protocols has set an industry benchmark in offshore safety.
  • Project Diamond Award:
    • SAFEEN MS – Vessel Traffic Management Information System (VTMIS) Project – The VTMIS project was recognised for its impact on maritime safety and operational efficiency. Integrating advanced tracking and monitoring systems, it has optimised vessel management, ensuring safe and efficient maritime operations within UAE waters.
  • Human Resources Gold Award:
    • AD Ports Group – Recognised for its strategic approach to human capital, the group’s Human Capital and Emiratisation unit has driven workforce engagement and development programs, fostering a productive work environment aligned with organisational goals.

Event Highlights:

The HBC 2024 Awards recognised 60 winners across 28 categories, representing over 5,000 assessment hours and 3,741 applications. With the global launch of the Intelligent Sustainable Excellence (ISE) Model and the introduction of the HBC Quality of Life Award, the event underscored a commitment to advancing standards that enhance societal well-being.

Congratulations to AD Ports Group and its awardees for their accomplishments. These awards underscore their dedication to excellence, innovation, and sustainability in port and maritime services.

For more information, please visit https://hbcworld.org/cases

Media Contact
Company Name: Harvard Business Council
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://hbcworld.org/cases

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AD Ports Group Recognised with Multiple Honors at HBC 2024 International Awards

Abu Dhabi Police Recognized with Multiple Honors at HBC 2024 International Awards

Abu Dhabi, UAE – Brigadier Dr. Rashid M. Bursheed and Lieutenant Colonel Expert Dr. Wafa Altayari from Abu Dhabi Police achieved outstanding recognition at the HBC 2024 International Awards held on November 9 in Riyadh. The ceremony celebrated international excellence and drew distinguished guests, including H.E. Almarri Lieutenant General Mohammed Ahmed, Director General of the General Directorate of Residency and Foreigners Affairs – Dubai; His Excellency Dr. Engineer Saad bin Ahmed Al Muhannadi, President of Qatar’s Public Works Authority; His Excellency Dr. Wahdan Al Qadi, CEO of the Saudi Investment Fund for Events; and Dr. Emmanuel Cerroni, Director General of HBC.

Achievements at HBC 2024:

  • Executives Diamond Award: Brigadier Dr. Rashid M. Bursheed, Deputy Director – Brigadier Dr.Bursheed was honored for his visionary leadership and commitment to advancing policing through the integration of future foresight tools, including AI, robotics, and metaverse technologies. His instrumental role in the ADP 2057 plan exemplifies his dedication to strategic development and innovation in police training.
  • Women Leader Gold Award: Lieutenant Colonel Expert Dr. Wafa Altayari– Dr. Altayari was recognized for her groundbreaking contributions to forensic science, innovation, and leadership. With a career spanning over a decade, she has led initiatives in DNA analysis, developed AI-based forensic tools, and contributed to groundbreaking advancements in forensic laboratory operations. Her leadership in transitioning the DNA branch to a fully digital system has saved significant operational time and resources, reinforcing her status as a role model for women leaders.


Event Highlights:

The HBC 2024 Awards recognized 60 winners across 28 categories, representing over 5,000 assessment hours and 3,741 applications. With the global launch of the Intelligent Sustainable Excellence (ISE) Model and the introduction of the HBC Quality of Life Award, the event underscored a commitment to advancing standards that enhance societal well-being.

Congratulations to Brigadier Dr. Rashid M. Bursheedand Dr. Wafa Altayari for their achievements. These awards underscore their commitment to innovation, excellence, and the future of police and security sciences.

For more information, please visit https://hbcworld.org/cases

Instagram: https://www.instagram.com/adpolicehq?igsh=MW5vZHdtOHZxcWd0bQ==

Media Contact
Company Name: Harvard Business Council
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://hbcworld.org/cases

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Abu Dhabi Police Recognized with Multiple Honors at HBC 2024 International Awards

Stuttering Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Emalex Biosciences

The Key Stuttering Companies in the market include – Emalex Biosciences, and others.

 

The Stuttering market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stuttering pipeline products will significantly revolutionize the Stuttering market dynamics.  

 

DelveInsight’s “Stuttering Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Stuttering, historical and forecasted epidemiology as well as the Stuttering market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Stuttering market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Stuttering market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Stuttering Market Forecast

 

Some of the key facts of the Stuttering Market Report: 

  • The Stuttering market size was valued approximately ~USD 40 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In April 2024, Noema Pharma’s NOE-105 experienced an increase in its Phase Transition Success Rate (PTSR) following the completion of a Phase IIb trial. The drug candidate’s PTSR for treating stuttering or stammering rose by nine points, reaching 56%. PTSR represents the likelihood, expressed as a percentage, of a drug successfully advancing from one development phase to the next.

  • In 2023, the EU4 countries and the UK collectively generated approximately USD 3.9 million, with expectations of significant compound annual growth. Within Europe, Germany and France held the largest market shares, followed by the UK and Italy, while Spain had the smallest market share for that year.

  • DelveInsight estimates that there were approximately 4,013,792 total prevalent cases of stuttering in the 7MM, with around 885,952 diagnosed prevalent cases in 2023. These numbers are expected to rise by 2034 due to better understanding of the condition and heightened awareness among healthcare professionals and the general public.

  • The total diagnosed prevalent cases of stuttering in the US were approximately 415,969,023. This number is expected to rise by 2034.

  • In 2023, the US accounted for about 47% of the total diagnosed prevalent cases of stuttering among the 7MM, with the EU4 and the UK making up nearly 38%, and Japan around 15%. These cases are expected to rise by 2034 due to improved diagnostic methods, resulting in more accurate identification and reporting globally.

  • According to DelveInsight’s analysis, in 2023, there was a gender-specific distribution of the disease showing male predominance, with approximately 664,464 cases, compared to around 221,488 cases in females among the total diagnosed prevalent cases in the 7MM. These numbers are expected to rise during the forecast period due to societal and cultural influences on reporting and diagnosis, possibly because males face less stigma or societal pressure to hide their speech difficulties compared to females.

  • Key Stuttering Companies: Emalex Biosciences, and others

  • Key Stuttering Therapies: Ecopipam (EBS-101), and others

  • The Stuttering epidemiology based on gender analyzed that males have higher prevalence rate than females with a ratio of 3:1

 

Stuttering Overview

Stuttering, also known as stammering, is a speech disorder characterized by disruptions in the flow of speech. These disruptions can include repetitions of sounds, syllables, or words, prolongations of sounds, and involuntary pauses or blocks where the person is unable to produce sounds. Stuttering can affect communication and may lead to social and emotional challenges.

 

Get a Free sample for the Stuttering Market Report:

https://www.delveinsight.com/report-store/stuttering-market

 

Stuttering Market  

The dynamics of the Stuttering market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034. 

“In conditions such as Stuttering, close collaboration among all stakeholders is important because collaborative studies and systematic data collection will help further in the understanding of disease pathophysiology. As a next step, a global prospective study will help all the research fraternity in better understanding of biomarkers and diagnostic tests which will be relevant for future therapeutic clinical trials.”

 

Stuttering Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Stuttering Epidemiology Segmentation:

The Stuttering market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Stuttering

  • Prevalent Cases of Stuttering by severity

  • Gender-specific Prevalence of Stuttering

  • Diagnosed Cases of Episodic and Chronic Stuttering

 

Download the report to understand which factors are driving Stuttering epidemiology trends @ Stuttering Epidemiological Insights

 

Stuttering Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Stuttering market or expected to get launched during the study period. The analysis covers Stuttering market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Stuttering Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

To know more about Stuttering treatment, visit @ Stuttering Medications

 

Stuttering Therapies and Key Companies

  • Ecopipam (EBS-101): Emalex Biosciences

 

Stuttering Market Drivers

  • Increasing prevalence

  • No approved drug (huge opportunity in the market)

  • Genetic findings

  • Increasing awareness in parents

 

Stuttering Market Barriers

  • Underdiagnoses

  • Treatment guidelines and recommendations are focused on non-pharmacologic therapy

  • Challenges in the management of the disease

  • Insufficient knowledge of the pathogenesis

 

Scope of the Stuttering Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Stuttering Companies: Emalex Biosciences, and others

  • Key Stuttering Therapies: Ecopipam (EBS-101), and others

  • Stuttering Therapeutic Assessment: Stuttering current marketed and Stuttering emerging therapies

  • Stuttering Market Dynamics: Stuttering market drivers and Stuttering market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Stuttering Unmet Needs, KOL’s views, Analyst’s views, Stuttering Market Access and Reimbursement 

 

Discover more about therapies set to grab major Stuttering market share @ Stuttering Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Stuttering Market Report Introduction

2. Executive Summary for Stuttering

3. SWOT analysis of Stuttering

4. Stuttering Patient Share (%) Overview at a Glance

5. Stuttering Market Overview at a Glance

6. Stuttering Disease Background and Overview

7. Stuttering Epidemiology and Patient Population

8. Country-Specific Patient Population of Stuttering 

9. Stuttering Current Treatment and Medical Practices

10. Stuttering Unmet Needs

11. Stuttering Emerging Therapies

12. Stuttering Market Outlook

13. Country-Wise Stuttering Market Analysis (2020–2034)

14. Stuttering Market Access and Reimbursement of Therapies

15. Stuttering Market Drivers

16. Stuttering Market Barriers

17.  Stuttering Appendix

18. Stuttering Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/blog/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stuttering Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Emalex Biosciences

New book “The 3-Piece Pawn Game™” by Eladio Alameda is released, a unique approach to learning chess that helps new players develop skill and gain understanding with ease

“The 3-Piece Pawn Game™: How to Learn Chess the Easy Way” by Eladio Alameda has been released worldwide. This guidebook introduces the fundamentals of chess through a new method of teaching called “The 3-Piece Pawn Game™,” which utilizes a reduced piece count focused on pawns, knights, and kings. This simplified, introductory game teaches new players core movements, rules, and basic strategies before expanding into the functions of other pieces and full game of classic chess. Through this unique method, many beginners are thrilled to discover they can start playing chess in as little as 15 minutes!

With diagrams, easy-to-follow instructions, sections for note taking, and handy review sections at the end of each chapter, the book demystifies the complexities of chess to get people playing and learning quickly. As the guide progresses, the author walks readers through example games to show stages of play and potential moves, and quotes from legendary chess masters inspire new players while teaching important elements of strategy.

Author Eladio “Coach Al” Alameda, a Certified Chess Coach of the U.S. Chess Federation, draws from three decades of experience teaching chess to beginners of all ages in this systematic, carefully constructed approach. By starting with The 3-Piece Pawn Game™, he gets novice players actively involved in games, solving the common problems of overwhelm and confusion that many beginners encounter when they tackle the full game at the outset of their chess journey. This allows beginners to experience the enjoyment (and challenges) of the game through bite-sized lessons that take fledgling players from their very first moves all the way through to more advanced tactics, terminology, and developmental approaches that last a lifetime. 

An incredible introduction for people of all ages and a valuable resource for players of all skill levels, Coach Al’s guide to both The 3-Piece Pawn Game™ and full game of chess provides the tools and inspiration to move toward mastery.

The 3-Piece Pawn Game™ (ISBN: 9781963844474) can be purchased through retailers worldwide, including Barnes & Noble and Amazon. The hardcover retails for $15.99 and the ebook retails for $3.99. Review copies and interviews are available upon request.

Learn more at: https://learnchesseasily.com/

From the back cover:

Welcome to the exciting world of chess! This book will guide you as you begin this journey. Chess is a game of intellectual depth and strategic brilliance, offering endless possibilities and challenges to captivate players of all ages and backgrounds. Chess is an educational tool that promotes critical thinking, problem-solving, decision-making, and concentration. It nurtures creativity, develops logical reasoning, and cultivates patience and resilience. Conventional methods of learning chess require you to learn all the pieces and each piece’s abilities at the same time. Many new players become discouraged by this and quickly hold back from learning chess. 

The 3-Piece Pawn Game™ is designed to facilitate learning and help you apply acquired skills in a short period of time. You will first learn to play using pawns, knights, and kinds. As we progress in The 3-Piece Pawn Game™, additional pieces are added one by one to complete the full game of chess. We’ll cover everything you need to know, from the movement of each piece to the basic principles of chess. We’ll introduce you to key chess terminology and notations, gradually building your understanding and confidence as you progress through the book. 

Learning chess is a gradual process, and mastery takes time. Don’t be discouraged by occasional setbacks or challenges along the way. Every great chess player started as a beginner. So, get ready to enter the fascinating world of chess. Whether you aspire to become a fierce competitor, enjoy friendly matches with friends and family, or engage your mind in a captivating game, this book will grant you the knowledge and skills to begin your chess adventure with confidence and enthusiasm. 

About the author:

Eladio Alameda, “Coach Al,” is a member of the U.S. Chess Federation. Coach Al has over 30 years of experience teaching chess. He has trained all levels, from beginners on, and had students with no prior knowledge of chess become city, state, and national champions.

Coach Al created The 3-Piece Pawn Game™, an easier and simpler way to learn how to play chess by minimizing the number of pieces at the beginning of the learning process. This makes players feel less pressure and have fewer options, so decision-making is kept simple. Thus, the game’s pace is quicker, and there is a clear way to win each match. 

Students learn fast, gain confidence, and progress quickly in understanding the full game of chess. Many beginners are delighted to learn they can start playing chess in as little as 15 minutes with The 3-Piece Pawn Game™ method. 

About MindStir Media:

MindStir Media LLC is an award-winning book publisher. To learn more about publishing a book with MindStir Media, visit http://mindstirmedia.com or call 800-767-0531.

Media Contact
Company Name: MindStir Media LLC
Contact Person: Jen McNabney
Email: Send Email
Phone: 800-767-0531
Address:1 New Hampshire Ave Suite 125
City: Portsmouth
State: NH
Country: United States
Website: https://mindstirmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New book “The 3-Piece Pawn Game™” by Eladio Alameda is released, a unique approach to learning chess that helps new players develop skill and gain understanding with ease

Future Electronics Celebrates Derek Lucas on His 25-Year Work Anniversary

Future Electronics Celebrates Derek Lucas on His 25-Year Work Anniversary
Future Electronics proudly celebrates Derek Lucas for 25 years of dedicated service and outstanding contributions to the company.

Montreal, Canada – November 29, 2024 – Future Electronics, a global leader in electronics components distribution, is delighted to commemorate the 25th work anniversary of Derek Lucas, an account executive within Future Electronics’ Inside Sales Team, whose career has been marked by dedication, professionalism, and excellence.

Derek began his journey with Future Electronics as a Marketing Support Representative. His career path within the company included roles as a Marketer and in TSG, before transitioning to a successful position in Sales. His outstanding work earned him the prestigious title of Infineon Future Electronics Inside Salesman of the Year in 2020, a testament to his skill and commitment.

Reflecting on Derek’s contributions, Scott Mawhinney, Sales Director at Future Electronics, shared, “Congratulations to Derek on 25 years of outstanding service to Future Electronics. Derek is a valued member of the Inside Sales team. He comes to work every day with a positive attitude, has great relationship-building skills internally and externally, and provides outstanding service to his customers. Congratulations on this remarkable milestone and many more years of success and growth ahead. Thank you for being such an integral part of our team!”

Outside of work, Derek enjoys a vibrant personal life, playing softball, traveling, and attending live sports events and concerts.

Future Electronics is committed to recognizing the dedication and hard work of its employees, fostering a supportive and rewarding work environment. Derek’s 25-year journey is a testament to the company’s culture of growth, community, and excellence. Future Electronics congratulates Derek on this significant milestone and looks forward to his continued success.

To learn about career opportunities at Future Electronics, visit the following link: https://www.futureelectronics.com/careers

About Future Electronics:

Founded in 1968, Future Electronics is a global leader in the electronic components industry. Future Electronics’ award-winning customer service, global supply chain programs and industry-leading engineering design services have made the company a strategic partner of choice.

Headquartered in Montreal, Canada, Future Electronics operates in 159 offices across 44 countries with over 5,000 employees. Its worldwide presence powers the company’s outstanding service and efficient, comprehensive global supply chain solutions. Future Electronics is globally integrated and supported by one IT infrastructure which provides real-time inventory availability and enables fully integrated operations, sales and marketing services worldwide. In 2024, Future became a WT Microelectronics company, now dual-headquartered in both Montreal, Canada and Taipei City, Taiwan.

Future Electronics’ mission is always to Delight the Customer®. For more information visit www.FutureElectronics.com.

Media Contact
Company Name: Future Electronics
Contact Person: Jamie Singerman
Email: Send Email
Phone: 514-694-7710
Address:237 Hymus Boulevard
City: Pointe Claire
State: Quebec
Country: Canada
Website: https://www.futureelectronics.com/

Single Ventricle Heart Disease Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma

The Key Single Ventricle Heart Disease Companies in the market include – Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion, Metcela, and others.

 

DelveInsight’s “Single Ventricle Heart Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Single Ventricle Heart Disease, historical and forecasted epidemiology as well as the Single Ventricle Heart Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Single Ventricle Heart Disease, offering comprehensive insights into the Single Ventricle Heart Disease revenue trends, prevalence, and treatment landscape. The report delves into key Single Ventricle Heart Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Single Ventricle Heart Disease therapies. Additionally, we cover the landscape of Single Ventricle Heart Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Single Ventricle Heart Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Single Ventricle Heart Disease space.

 

To Know in detail about the Single Ventricle Heart Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Single Ventricle Heart Disease Market Forecast

 

Some of the key facts of the Single Ventricle Heart Disease Market Report: 

  • The Single Ventricle Heart Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In Spetember 2024, Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a biopharmaceutical company specializing in muscle diseases, has announced top-line results for EDG-7500 from its Phase 1 trial in healthy participants and the single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy (HCM). EDG-7500 is an innovative oral, selective cardiac sarcomere modulator developed to reduce early contraction velocity and improve impaired cardiac relaxation linked to HCM.

  • Key Single Ventricle Heart Disease Companies: Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion, Metcela, and others

  • Key Single Ventricle Heart Disease Therapies: Udenafil, AZD1305, Bosentan, Captopril, BAY1142524, QVA149, Ivabradine, REGN5381, Macitentan, JRM-001, and others

  • The Single Ventricle Heart Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Single Ventricle Heart Disease pipeline products will significantly revolutionize the Single Ventricle Heart Disease market dynamics.

  • The analysis of single ventricle heart disease revealed that these defects are uncommon, affecting approximately five in every 100,000 newborns. They are also among the most complex heart conditions, typically necessitating at least one surgical intervention.

  • The analysis found that the most prevalent congenital heart defects (ACHDs) include atrial septal defect (20.5%), ventricular septal defect (20.5%), tetralogy of Fallot (12.9%), and univentricular heart (UVH)/single ventricle (SV) (6.6%).

  • It was discovered that hypoplastic left heart syndrome, the most prevalent type of univentricular heart disease, occurs in 2 to 3 out of every 10,000 births, with a higher incidence in males.

  • The analysis revealed that double outlet right ventricle occurs in 0.009 cases per 10,000 live births, while double inlet left ventricle is seen in up to 0.01 cases per 10,000 live births.

  • The analysis found that tricuspid atresia occurs in approximately 1 in every 10,000 live births, while Ebstein anomaly is seen in about 0.5 per 10,000 live births, with a noted gender preference.

 

Single Ventricle Heart Disease Overview

Single Ventricle Heart Disease (SVHD) is a rare congenital heart defect where one of the heart’s ventricles is underdeveloped or missing. This condition disrupts the normal flow of blood, as the heart cannot effectively pump oxygenated blood to the body and deoxygenated blood to the lungs.

 

Get a Free sample for the Single Ventricle Heart Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/single-ventricle-heart-disease-market

 

Single Ventricle Heart Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Single Ventricle Heart Disease Epidemiology Segmentation:

The Single Ventricle Heart Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Single Ventricle Heart Disease

  • Prevalent Cases of Single Ventricle Heart Disease by severity

  • Gender-specific Prevalence of Single Ventricle Heart Disease

  • Diagnosed Cases of Episodic and Chronic Single Ventricle Heart Disease

 

Download the report to understand which factors are driving Single Ventricle Heart Disease epidemiology trends @ Single Ventricle Heart Disease Epidemiology Forecast

 

Single Ventricle Heart Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Single Ventricle Heart Disease market or expected to get launched during the study period. The analysis covers Single Ventricle Heart Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Single Ventricle Heart Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Single Ventricle Heart Disease Therapies and Key Companies

  • Udenafil: Mezzion Pharma Co

  • AZD1305: AstraZeneca

  • Bosentan: Rigshospitalet

  • Captopril: Astrazeneca

  • BAY1142524: Bayer

  • QVA149: Novartis

  • Ivabradine: Amgen

  • REGN5381: Regeneron Pharma

  • Macitentan: Actelion

  • JRM-001: Metcela

 

Discover more about therapies set to grab major Single Ventricle Heart Disease market share @ Single Ventricle Heart Disease Treatment Landscape

 

Single Ventricle Heart Disease Market Drivers

  • Increasing Awareness and Early Diagnosis

  • Advancements in Surgical Techniques

  • Growing Focus on Pediatric Cardiology

  • Development of Novel Therapies

  • Supportive Government Initiatives

  • Improved Post-Surgical Care

  • Increasing Healthcare Accessibility

 

Single Ventricle Heart Disease Market Barriers

  • High Treatment Costs

  • Limited Awareness in Low-income Regions

  • Complexity of Treatment

  • Long-term Health Risks

  • Challenges in Personalized Medicine

  • Risk of Heart Transplantation

  • Limited Market Size

 

Scope of the Single Ventricle Heart Disease Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Single Ventricle Heart Disease Companies: Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma, Actelion, Metcela, and others

  • Key Single Ventricle Heart Disease Therapies: Udenafil, AZD1305, Bosentan, Captopril, BAY1142524, QVA149, Ivabradine, REGN5381, Macitentan, JRM-001, and others

  • Single Ventricle Heart Disease Therapeutic Assessment: Single Ventricle Heart Disease current marketed and Single Ventricle Heart Disease emerging therapies

  • Single Ventricle Heart Disease Market Dynamics: Single Ventricle Heart Disease market drivers and Single Ventricle Heart Disease market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Single Ventricle Heart Disease Unmet Needs, KOL’s views, Analyst’s views, Single Ventricle Heart Disease Market Access and Reimbursement 

 

To know more about Single Ventricle Heart Disease companies working in the treatment market, visit @ Single Ventricle Heart Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Single Ventricle Heart Disease Market Report Introduction

2. Executive Summary for Single Ventricle Heart Disease

3. SWOT analysis of Single Ventricle Heart Disease

4. Single Ventricle Heart Disease Patient Share (%) Overview at a Glance

5. Single Ventricle Heart Disease Market Overview at a Glance

6. Single Ventricle Heart Disease Disease Background and Overview

7. Single Ventricle Heart Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Single Ventricle Heart Disease 

9. Single Ventricle Heart Disease Current Treatment and Medical Practices

10. Single Ventricle Heart Disease Unmet Needs

11. Single Ventricle Heart Disease Emerging Therapies

12. Single Ventricle Heart Disease Market Outlook

13. Country-Wise Single Ventricle Heart Disease Market Analysis (2020–2034)

14. Single Ventricle Heart Disease Market Access and Reimbursement of Therapies

15. Single Ventricle Heart Disease Market Drivers

16. Single Ventricle Heart Disease Market Barriers

17.  Single Ventricle Heart Disease Appendix

18. Single Ventricle Heart Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/blog/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Single Ventricle Heart Disease Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Mezzion Pharma Co, AstraZeneca, Rigshospitalet, Bayer, Novartis, Amgen, Regeneron Pharma

iDenfy takes a huge step in its US expansion plan with a new office in Delaware

With the new year just around the corner, iDenfy sets bigger plans and continues to scale both in the EU and, now, the USA

 

Kaunas, Lithuania – November 29, 2024 – iDenfy, a leading global RegTech service provider for tools like Know Your Customer (KYC), Anti-Money Laundering (AML), and Know Your Business (KYB) verification, is excited to announce the opening of its newest office in Delaware, USA. This expansion is an important step in iDenfy’s journey to strengthen its presence in North America and better serve its growing client community with innovative AI tools tailored to meet the unique demands of the US compliance market.

With an increasing number of customers across the US, iDenfy understands the importance of being closer to its customers to meet their unique legal and compliance needs. The new office will allow iDenfy to provide more personalized support and customized solutions that meet the specific requirements of US-based companies. According to Domantas Ciulde, the CEO and Co-Founder of iDenfy, this is a huge step for their RegTech platform since its primary headquarters were opened in Kaunas, Lithuania, in 2017.

Currently, the company has over 50 in-house specialists, including compliance officers, developers, marketing experts, and other key roles. With the new office and plans to accelerate growth in 2025, iDenfy’s team is set to expand even further. iDenfy will also increase its local team in the US. The company is focused on hiring compliance and partnership enablement specialists, further strengthening its ability to deliver cutting-edge solutions while maintaining the highest trust and innovation standards.

Part of iDenfy’s success, especially with no outside help from investors, according to Domantas Ciulde, is transparent communication with all team members, giving opportunities to achieve new personal career goals while building RegTech products from scratch. For example, iDenfy doesn’t outsource IT specialists, and most of their front and back-end developers have been working in the company for at least three years, which is the stage where the company increased its service package significantly and added vital tools like KYB verification, automated risk assessment, bank verification, and others, uniquely tailored to different industries.

For example, identity verification now has multiple use cases, and iDenfy wanted to keep up with the potential of the technology, making it even better on their platform. When looking into the US market, stricter regulations, such as age verification requirements for age-restricted service providers or even social media sites, have already become mandatory in some states, opening new capabilities to partner with online platforms and offer them robust, user-friendly solutions. iDenfy’s advanced identity verification system is developed to analyze and recognize face biometrics to verify individuals’ age, ensuring compliance with these new regulatory standards.

The same goes for digital asset service providers or fintech platforms that need to check different data points about the user and, sometimes, implement address verification checks or extra proof of income verification steps, depending on the level of due diligence. iDenfy’s solution is fully customizable, and, according to Domantas Ciulde, they’re ready to provide the required building blocks in the US market.

“We’ve experienced significant growth in North American customer demand, especially in industries with stringent regulatory requirements,” said Domantas Ciulde. “The opening of the Delaware office allows us to more effectively meet these legal requirements and, more importantly, build strong long-term relationships with our partners in the US.”

iDenfy is already certified by the California Consumer Privacy Act (CCPA), showcasing its commitment to privacy and compliance with stringent U.S. data protection laws. The platform’s adaptability is further reinforced by a focus on customizable user interfaces, enhancing partners experiences across industries such as fintech, e-commerce, and blockchain.

It’s worth mentioning that the Delaware office will serve as a key hub for collaboration and future growth, reflecting iDenfy’s commitment to setting the standard for identity verification and fraud prevention globally. Currently, iDenfy is one of the few AI-powered solution providers that offers KYC, KYB, and AML features in a single dashboard.

About iDenfy  

iDenfy, a RegTech platform best known for its wide variety of identity verification services and fraud prevention tools, ensures AML, KYC, and KYB compliance for every company — from large-scale businesses to small organizations in industries like FinTech, iGaming, cryptocurrency, e-commerce, and more. The rapidly growing business was named the best Fintech Startup in 2020.  Recently, iDenfy was featured in G2’s Winter 2024 report as the number-one AML software.

For more information and business inquiries, please visit www.idenfy.com.

Media Contact
Company Name: IDenfy
Contact Person: Aurimas Kybartas
Email: Send Email
Phone: +37067644539
Country: Lithuania
Website: www.idenfy.com

Grand Opening of The 2nd Vocational Skills Competition of Hubei Provincial

Wuhan – The 2nd Vocational Skills Competition of Hubei Provincial is being held from November 28 to 30 at the Wuhan International Expo Center. This event is divided into five major sections: “Competition, Conference, Exhibition, Performance, and Recruitment,” providing a comprehensive platform to showcase the achievements of Hubei’s skilled talent development and offering skilled professionals the opportunity to demonstrate their expertise and engage in technical exchanges.

This competition is the highest-level, largest-scale, most diverse, and most influential comprehensive vocational skills event in Hubei,and it is featuring 99 competition categories. Forty key projects from manufacturing, life services, and digital technology sectors are selected for the final competition. The event aligns with international and national standards, with Chinese experts overseeing the judging process. Awards will be given in both individual and team categories, and the results will determine Hubei’s participants for the Third National Vocational Skills Competition of the People’s Republic of China.

Additionally, the event will feature the “Skill-Promoting Jingchu” 2024 Hubei Skills Achievements Exhibition, where 36 companies will showcase innovations in fields such as new energy vehicles, smart construction, drones, 3D printing, and industrial robotics.

Beyond being a competition arena for skilled talent, the event also serves as a recruitment platform. With a focus on matching skilled professionals with employers, the job fair will attract over 100 renowned companies from across Hubei and beyond, offering more than 3,000 high-quality job opportunities to ensure efficient, mutual matches between job seekers and employers.

The 2nd Vocational Skills Competition of Hubei Provincial not only provides a stage for skilled individuals to showcase their talents and achieve their dreams but also highlights Hubei’s exceptional skilled workforce and the unique cultural charm of Jingchu.

The opening and closing ceremonies of the competition are organized by Hubei Media Group.

Media Contact
Company Name: Open Hubei(HICC)
Contact Person: Li Xin
Email: Send Email
Country: China
Website: http://www.hbgbdst.com

Gold Mining Company to Launch Tokenized RWA Asset on Binance Smart Chain: Introducing GoldReserve

A new era in gold investment is set to begin with the launch of GoldReserve, a revolutionary tokenized asset (RWA) backed by real-world gold mining operations. Built on the Binance Smart Chain (BSC), GoldReserve is designed to democratize access to gold investments by combining the intrinsic value of gold with the transformative potential of blockchain technology.

Developed by a licensed mining company, GoldReserve aims to bridge the gap between traditional commodity markets and digital assets, offering a unique opportunity for investors to participate in a secure, transparent, and globally accessible platform.

Innovative Token Model

GoldReserve introduces a forward-thinking approach to integrating gold mining profitability with blockchain features:

  1. Monthly Buyback and Burn:

    • 10% of net mining profits will be allocated monthly for token buyback and burn. This reduces token supply over time, enhancing scarcity and supporting long-term value growth.

  2. Rewards for NFT Holders:

    • An additional 5% of net profits will be distributed monthly to holders of GoldReserve NFTs, providing a passive income stream directly linked to gold production.

Project Projections and Impact

With mining production capable of reaching 5 kg of gold per day, the monthly financial impact for token holders and NFT investors is substantial:

  • R$3.8 million (1,136 BNB) earmarked for buyback and burn.

  • R$1.9 million (568 BNB) to be distributed to NFT holders.

These figures underscore the immense potential of GoldReserve as both an investment vehicle and a disruptive force in the tokenized asset space.

Key Features and Advantages

GoldReserve offers investors the opportunity to gain exposure to a tangible, stable asset while benefiting from blockchain’s accessibility and transparency.

  • Deflationary Model:The buyback and burn mechanism ensures continuous token scarcity, driving long-term value appreciation.

  • Simplified Gold Investment:Token holders indirectly participate in gold mining profits without the logistical complexities of owning physical gold.

  • Full Transparency:Real-time blockchain updates provide investors with detailed insights into mining operations and profit allocation.

  • Global Accessibility:By leveraging blockchain, GoldReserve removes traditional geographic and regulatory barriers, allowing anyone to invest in the gold market.

Tokenomics Overview

  • Transaction Fee: 8% on all buy/sell transactions.

  • Total Supply: 1 billion tokens, with 40% burned at launch to enhance scarcity.

  • Security Measures: A fully audited smart contract and renounced ownership will ensure maximum investor protection.

NFT Rewards System

GoldReserve will launch an exclusive NFT collection that grants holders a share of 5% of net mining profits, offering a reliable source of passive income. With operations scaling to double shifts, this initiative will provide NFT holders with enhanced earnings potential as mining capacity expands.

A Transformative Opportunity

GoldReserve is poised to redefine the gold investment landscape, delivering a secure, transparent, and rewarding platform for investors seeking exposure to both physical gold and blockchain innovation.

Mark the Date: The official launch is scheduled for December 6, 2024, opening the door to a new chapter in tokenized asset investments.

About GoldReserve

GoldReserve is a cutting-edge tokenized asset platform developed by a licensed gold mining company. Combining the stability of gold with blockchain’s transparency and accessibility, GoldReserve offers a new paradigm for investment, ensuring secure and equitable access to one of the world’s most valuable commodities.

For more information, visit:

Website: www.goldreserverwa.com

Telegram: https://t.me/GoldReserveRWA

Twitter: https://x.com/gold_reserv?s=21

Instagram: https://www.instagram.com/goldreserveoficial

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: GoldReserverwa.com
Contact Person: Marcos Rodrigo
Email: Send Email
Address:Alameda Vicente Pinzon, 54 – Vila Olímpia
City: São Paulo
Country: Brazil
Website: https://goldreserverwa.com